As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delay

As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delay
aliu
Wed, 03/30/2022 – 10:06